--- title: "Armata Pharmaceuticals (ARMP) news: going concern" url: "https://aibio.space/companies/armata-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ARMP going concern news: Armata Pharmaceuticals flags going concern paragraph, gets $4.65 million from DoD. Armata Pharmaceuticals, Inc." --- ARMP Armata Pharmaceuticals, Inc. AMEX · United States # Armata Pharmaceuticals (ARMP) news ARMP going concern news Debt Financing · 2026-05-13 ## [Armata Pharmaceuticals takes $25 million secured loan from Innoviva](https://aibio.space/news/armata-pharmaceuticals-takes-25-million-secured-loan-innoviva/) The 14.0% term loan matures in January 2029 and is secured by substantially all of the company's assets. The lender is a subsidiary of Innoviva, which the filing describes as a principal shareholder. ## Latest Armata Pharmaceuticals news 1. 2026-05-13 Debt Financing [Armata Pharmaceuticals signs $25 million secured loan with Innoviva at 14.0%](https://aibio.space/news/armata-pharmaceuticals-signs-25-million-secured-loan-innoviva-14-0/) The term loan from Innoviva Strategic Opportunities LLC matures January 11, 2029 and is secured by substantially all company assets. Armata reported about $4.8 million of unrestricted cash and cash equivalents at March 31, 2026. 2. 2025-08-12 Debt Financing [Armata Pharmaceuticals enters $15 million secured term loan with Innoviva at 14.0% interest](https://aibio.space/news/armata-pharmaceuticals-enters-15-million-secured-term-loan-innoviva-14/) A $15 million loan from a unit of Armata's largest shareholder, Innoviva, carries a 14.0% rate, is secured by substantially all of the company's assets and matures in January 2029. Cash stood at $4.3 million on June 30, 2025. 3. 2025-05-01 Listings [Armata Pharmaceuticals flags going concern paragraph, gets $4.65 million from DoD](https://aibio.space/news/armata-pharmaceuticals-flags-going-concern-paragraph-gets-4-65-million/) The audit opinion in Armata's 2024 annual report contains a going concern explanatory paragraph. The company also received $4.65 million of additional Department of Defense award funding. 4. 2025-03-12 Debt Financing [Armata Pharmaceuticals signs $10 million loan from largest holder Innoviva at 14.0%](https://aibio.space/news/armata-pharmaceuticals-signs-10-million-loan-largest-holder-innoviva/) The secured term loan matures on March 12, 2026. Armata also pushed back the maturity of three earlier Innoviva credit agreements to the same date. ## Armata Pharmaceuticals at a glance - **Ticker**: ARMP - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $24.0 million ### Related companies - [Vincerx Pharma](https://aibio.space/companies/vincerx-pharma/) OTC: VINC - [Agenus](https://aibio.space/companies/agenus/) NASDAQ: AGEN - [Scribe Therapeutics](https://aibio.space/companies/scribe-therapeutics/) NASDAQ: SCTX - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD - [Halberd](https://aibio.space/companies/halberd/) OTC: HALB - [PMV Pharmaceuticals](https://aibio.space/companies/pmv-pharmaceuticals/) NASDAQ: PMVP - [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) NASDAQ: LRMR - [Summit Therapeutics](https://aibio.space/companies/summit-therapeutics/) NASDAQ: SMMT ### Also on AMEX - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AIM - [NanoViricides](https://aibio.space/companies/nanoviricides/) NNVC - [Apimeds Pharmaceuticals US](https://aibio.space/companies/apimeds-pharmaceuticals-us/) APUS - [Theriva Biologics](https://aibio.space/companies/theriva-biologics/) TOVX - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) KAPA - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) EDVA ## What Armata Pharmaceuticals does Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity and potency, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company describes phages as a potentially safer alternative to broad-spectrum antibiotics that can preserve the normal human microbiome. Its first candidate, inhaled AP-PA02, targets chronic pulmonary infections due to Pseudomonas aeruginosa. AP-PA02 completed a Phase 1b/2a study in cystic fibrosis, supported by a $5.0 million Therapeutics Development Award from the CFF, and a Phase 2 study in non-cystic fibrosis bronchiectasis (NCFB) called Tail wind. The company reports that Tail wind results, announced December 19, 2024, showed a durable reduction of P. aeruginosa in the lung with a favorable safety and tolerability profile. A second candidate, AP-SA02, targets a different bacterial pathogen. The company says it has completed three Phase 2 clinical trials to date. It also describes manufacturing improvements that increase phage titers and purity. | Product or program | What it is | Stage | |---|---|---| | AP-PA02 | Inhaled phage therapy for chronic Pseudomonas aeruginosa lung infections | Phase 2 completed in NCFB | | AP-SA02 | Phage candidate targeting a second bacterial pathogen | clinical candidate | Summarised from the company's [10-K filed Mar 25, 2026](https://www.sec.gov/Archives/edgar/data/921114/000110465926034532/armp-20251231x10k.htm). ## Armata Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$173.8 million](https://www.sec.gov/Archives/edgar/data/921114/000110465926034532/) | [-$18.9 million](https://www.sec.gov/Archives/edgar/data/921114/000110465926034532/) | | Cash from operations | [-$25.8 million](https://www.sec.gov/Archives/edgar/data/921114/000110465926034532/) | [-$37.6 million](https://www.sec.gov/Archives/edgar/data/921114/000110465926034532/) | | Cash and equivalents | [$8.7 million](https://www.sec.gov/Archives/edgar/data/921114/000110465926094907/) | [$9.3 million](https://www.sec.gov/Archives/edgar/data/921114/000110465926034532/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $24.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Armata Pharmaceuticals Has Armata Pharmaceuticals issued a going-concern warning? Our latest story on this, dated May 1, 2025: "Armata Pharmaceuticals flags going concern paragraph, gets $4.65 million from DoD". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/armata-pharmaceuticals-flags-going-concern-paragraph-gets-4-65-million/). What is the ticker symbol of Armata Pharmaceuticals? Armata Pharmaceuticals, Inc. trades under the ticker ARMP on AMEX. Where is Armata Pharmaceuticals listed? Armata Pharmaceuticals, Inc. is listed on AMEX. Our directory also records these other listings: GETTEX:TG1N; LS:A2PKLC; LSX:A2PKLC. What is the SEC CIK of Armata Pharmaceuticals? The SEC Central Index Key (CIK) for Armata Pharmaceuticals, Inc. is 921114. Its filings are on SEC EDGAR. How many shares does Armata Pharmaceuticals have outstanding? 37,181,979 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Armata Pharmaceuticals listed under? Our directory records Armata Pharmaceuticals, Inc. under United States. What does Armata Pharmaceuticals do? Our directory classifies Armata Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Armata Pharmaceuticals? The ISIN recorded for Armata Pharmaceuticals, Inc. is US04216R1023. Does aibio.space cover Armata Pharmaceuticals? aibio.space lists Armata Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Armata Pharmaceuticals incorporated? SEC records list its state or country of incorporation as WA. What does Armata Pharmaceuticals develop? Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity and potency, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company describes phages as a potentially safer alternative to broad-spectrum antibiotics that can preserve the normal human microbiome. What is AP-PA02 from Armata Pharmaceuticals? AP-PA02: Inhaled phage therapy for chronic Pseudomonas aeruginosa lung infections Stage: Phase 2 completed in NCFB. What is AP-SA02 from Armata Pharmaceuticals? AP-SA02: Phage candidate targeting a second bacterial pathogen Stage: clinical candidate. Is Armata Pharmaceuticals profitable? Armata Pharmaceuticals, Inc. reported a net loss of $173.8 million for the fiscal year ended Dec 31, 2025, and used $25.8 million of cash in operations, per its annual report to the SEC. How much cash does Armata Pharmaceuticals have? $24.0 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Armata Pharmaceuticals Members talk about Armata Pharmaceuticals (ARMP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Armata Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2025-12-01 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/921114/000110465925117382/tm2532031d1_424b5.htm) 2. 2025-05-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/921114/000110465925043017/tm2513778d1_ex99-1.htm) 3. 2025-03-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/tm258929d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:ARMP on TradingView](https://www.tradingview.com/symbols/AMEX-ARMP/). ## SEC filings and registration - **SEC name**: Armata Pharmaceuticals, Inc. - **CIK**: 921114 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ARMP (NYSE) - **State or country of incorporation**: WA - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 5005 MCCONNELL AVE, LOS ANGELES, CA, 90066 - **Phone**: 310-665-2928 - **Shares outstanding**: 37,181,979 as of 2026-08-06 (10-Q filed 2026-08-12) - **Former names**: AmpliPhi Biosciences Corp; TARGETED GENETICS CORP /WA/ ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/921114/000110465926109809/tm2625977d1_8k.htm) filed 2026-09-23 - [8-K](https://www.sec.gov/Archives/edgar/data/921114/000110465926107253/tm2625289d1_8k.htm) filed 2026-09-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/921114/000110465926094907/armp-20260630x10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/armp-20260812x8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/tm2620782d2_8k.htm) filed 2026-07-20 - [8-K](https://www.sec.gov/Archives/edgar/data/921114/000110465926084860/tm2620782d1_8k.htm) filed 2026-07-20 - [8-K](https://www.sec.gov/Archives/edgar/data/921114/000110465926082850/tm2620286d1_8k.htm) filed 2026-07-13 - [8-K](https://www.sec.gov/Archives/edgar/data/921114/000110465926076627/tm2618503d1_8k.htm) filed 2026-06-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000921114), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Armata Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker ARMP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Armata Pharmaceuticals, Inc. - **Ticker**: ARMP - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US04216R1023 - **Other listed symbols**: GETTEX:TG1N; LS:A2PKLC; LSX:A2PKLC - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-ARMP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/armata-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Armata Pharmaceuticals (ARMP) news: going concern", 2026-10-31, https://aibio.space/companies/armata-pharmaceuticals/